An update of novel therapeutic approaches for multiple myeloma

被引：9
作者：
Richardson P. [1 ]
Hideshima T. [1 ]
Anderson K.C. [1 ]
机构：
[1] Dana-Farber Cancer Institute, Boston, MA 02115
来源：
Current Treatment Options in Oncology | 2004年 / 5卷 / 3期
关键词：
Multiple Myeloma; Thalidomide; Bortezomib; Arsenic Trioxide; Multiple Myeloma Cell;
D O I：
10.1007/s11864-004-0014-6
中图分类号：
学科分类号：
摘要：
Multiple myeloma (MM) remains an incurable malignancy, despite conventional and high-dose therapies, and novel biologically based treatment approaches are urgently needed. Recent studies have characterized the molecular mechanisms by which MM cell/host bone marrow (BM) interactions regulate tumor cell growth, survival, and migration in the BM milieu. These studies have not only enhanced our understanding of disease pathogenesis, but they have also provided the framework for a new treatment paradigm targeting the MM cell in its BM microenvironment to overcome drug resistance and improve patient outcome. Clinical trials are confirming the remarkable activity and improved tolerability of some of the new agents identified through this paradigm, providing exciting evidence of translational success in MM. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：227 / 238
页数：11
相关论文
共 100 条
  • [1] Kuehl W.M., Bergsagel P.L., Multiple myeloma: Evolving genetic events and host interactions, Nat. Rev. Cancer, 2, pp. 175-187, (2002)
  • [2] Anderson K.C., Targeted therapy for multiple myeloma, Semin. Hematol., 38, pp. 286-297, (2001)
  • [3] Gregory W.M., Richards M.A., Malpas J.S., Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials, J. Clin. Oncol., 10, pp. 334-342, (1992)
  • [4] Attal M., Harousseau J.L., Randomized trial experience of the Intergroupe Francophone du Myelome, Semin. Hematol., 38, pp. 226-230, (2001)
  • [5] Desikan R., Barlogie B., Sawyer J., Et al., Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities, Blood, 95, pp. 4008-4010, (2000)
  • [6] Attal M., Harousseau J.L., Facon T., Et al., Single versus double autologous stem cell transplant for multiple myeloma, N. Engl. J. Med., 349, pp. 2495-2502, (2003)
  • [7] Massaia M., Borrione P., Battaglio S., Et al., Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy, Blood, 94, pp. 673-683, (1999)
  • [8] Gahrton G., Tura S., Ljungman P., Et al., Allogeneic bone marrow transplantation in multiple myeloma, N. Engl. J. Med., 325, pp. 1267-1273, (1991)
  • [9] Gahrton G., Svensson H., Cavo M., Et al., Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow centers, Br. J. Haematol., 113, pp. 209-216, (2001)
  • [10] Alyea E., Weller E., Schlossman R., Et al., T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect, Blood, 98, pp. 934-939, (2001)
12345678910